Drug Info Aging postmenopausal women are always at high risk of fracture. Osteoporosis is a serious health problem associated with significant morbidity and mortality in postmenopausal women. Denosumab is a drug of choice for the treatment in such cases. This drug molecule info focuses on its indication and contraindications and precautions. Denosumab is a biological agent and the first monoclonal antibody for the treatment of postmenopausal osteoporosis.
It is an IgG2 antibody that inhibits RANKL (receptor activator of nuclear factor kappa B ligand) and prevents the information, function and survival of osteoclasts thereby decreasing bone loss and resorption. RANKL is a protein essential for activation and function of osteoblasts. Indications: Denosumab is indicated for Osteoporosis: primarily in postmenopausal women and it is indicated in men for who are at high risk of fracture. Bone…
